The potential role of Aurora kinase inhibitors in haematological malignancies.
about
Small-molecule inhibitors of the Myc oncoproteinPhase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomasA phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.Targeting the protein kinases for anti-cancer therapy.Aurora A kinase expression is increased in leukemia stem cells, and a selective Aurora A kinase inhibitor enhances Ara-C-induced apoptosis in acute myeloid leukemia stem cells.Targeted drug discovery for pediatric leukemia.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Posttranslational modifications of the retinoblastoma tumor suppressor protein as determinants of function.Emerging drugs for acute lymphocytic leukemia.Stathmin 1 in normal and malignant hematopoiesis.Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).Mechanisms and clinical applications of chromosomal instability in lymphoid malignancy.The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models.Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.Excess F-actin mechanically impedes mitosis leading to cytokinesis failure in X-linked neutropenia by exceeding Aurora B kinase error correction capacityDownregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype.The Ski Protein is Involved in the Transformation Pathway of Aurora Kinase A.Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors.CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors.Aurora B kinase in Hodgkin lymphoma: immunohistochemical pattern of expression in neoplastic Hodgkin and Reed-Sternberg cells.Specific immune responses against epitopes derived from Aurora kinase A and B in acute myeloid leukemia.MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.Therapeutic polymeric nanoparticles and the methods of making and using thereof: a patent evaluation of WO2015036792.A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia
P2860
Q27025648-27872609-6F93-49D7-9192-FC5B6A0E68C6Q33410380-E73D783E-5DC9-48DD-9AA4-F8BA53D50ED3Q33897070-341F7A84-A377-48F7-B14A-07063217A00BQ33952803-D24F4A2F-DF5C-4B23-8E8F-776332FB352CQ34448958-891A53D8-F601-4260-A2A0-B5C52A739E64Q36297631-521CEF1C-5A8A-4F69-9DAA-4B69AA59D918Q36297651-D631D51D-4454-4356-9EFB-A37291859045Q36989223-183D8A65-8986-4419-ADFC-C79DC0BBCE60Q37697253-BA6BEE78-49E7-4519-A166-351E55627A17Q38103250-96198870-FB16-480F-AD64-AE307933001FQ38172586-48A56397-4EC1-4A8E-8AF8-6C98DB5FF153Q38199283-1C9EE653-19F8-4A79-85F7-9884C8B92D26Q38223271-4A05E6E6-DF1E-4FB7-B055-B17749BB5FD5Q38504989-CE7889D0-B2D7-4ADE-919A-7114E0A76CF3Q38847105-9A479A01-29A8-41C0-B940-FE62E0C2C23CQ38920820-4DD43B36-10A7-45A6-A493-F7A8DEA03237Q39279911-BAB4F152-7009-413A-A789-3CAA479B3E1CQ39515650-83D614AC-0D79-4C9D-B3BD-16776423254BQ40772862-77809F3F-3CEF-4B43-A7A8-30BDD592768FQ48104415-3CA1DFD0-882C-4219-A075-9494451396CEQ51752158-9735F016-E5DA-42A0-96C2-884125C90C8EQ53075287-296EECB1-8E4E-475B-9071-620EDBDB3212Q53076735-171F1339-F39A-4092-8F8B-6C83322E2EDBQ54475024-4E1DEA9A-A1A7-48CF-8809-253869D80CEFQ54498929-87C934C8-0B3A-45CF-8FFB-821198390DAAQ55022875-592D1852-1DE3-4041-B911-3E51727BF29BQ58414303-41B8C694-F8E9-4B42-9C13-615465DB2D4E
P2860
The potential role of Aurora kinase inhibitors in haematological malignancies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 October 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The potential role of Aurora kinase inhibitors in haematological malignancies.
@en
The potential role of Aurora kinase inhibitors in haematological malignancies.
@nl
type
label
The potential role of Aurora kinase inhibitors in haematological malignancies.
@en
The potential role of Aurora kinase inhibitors in haematological malignancies.
@nl
prefLabel
The potential role of Aurora kinase inhibitors in haematological malignancies.
@en
The potential role of Aurora kinase inhibitors in haematological malignancies.
@nl
P2860
P1476
The potential role of Aurora kinase inhibitors in haematological malignancies.
@en
P2093
Sherif S Farag
P2860
P304
P356
10.1111/J.1365-2141.2011.08898.X
P407
P577
2011-10-08T00:00:00Z